Inhibition of PRMT1 in triple-negative breast cancer (TNBC) cells triggers an interferon response, leading to cell death [68], and disrupts chromatin recruitment, enhancing cisplatin efficacy [69]. The gene discussed is PRMT1; the disease is triple-negative breast carcinoma.